Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
CRISPR Therapeutics
ISIN CH0334081137
|WKN A2AT0Z
Market cap (in EUR)
4,709 m
Country
Switzerland
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Healthcare Biopharmaceuticals Other Biopharmaceuticals Switzerland
Financials
Key metrics
| Market capitalisation, EUR | 4,709 m |
| EPS, EUR | -5.05 |
| P/B ratio | 2.8 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 34 m |
| Net income, EUR | -339 m |
| Profit margin | -981.54% |
What ETF is CRISPR Therapeutics in?
There are 40 ETFs which contain CRISPR Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of CRISPR Therapeutics is the ARK Genomic Revolution UCITS ETF USD Accumulating.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.